The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
From Multimodal biomedical AI (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [118]
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [27]
In the citing paper
“Cancer genome sequencing efforts yielded an unexpected discovery in 2008 with the identification of somatic mutations in a metabolic enzyme, the TCA cycle enzyme IDH1, in glioblastoma multiforme (GBM) (77).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [77]
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,713
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citation
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- H. Scherer, Am. J. Cancer40, 159 (1940).
- R. J. Learyet al. Proc. Natl. Acad. Sci. U.S.A. in press.
- K. Uekiet al., Cancer Res.56, 150 (1996).
- L. Frederick, X. Y. Wang, G. Eley, C. D. James, Cancer Res.60, 1383 (2000).
- G. Thielet al., Anticancer Res.15, 2495 (1995).
- S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Methods Mol. Biol.356, 319 (2007).
- Contact information for the authors who directed the major components of this project is as follows: H. Yan G. J. Riggins (clinical and sample coordination) yan00002@mc.duke.edu griggin1@jhmi.edu; D. D. Bigner (pathological and clinical review) bigne001@mc.duke. edu; R. Karchin (bioinformatic analysis) karchin@jhu.edu; N. Papadopoulos (gene expression analysis) npapado1@jhmi.edu; G. Parmigiani (statistical analysis) gp@jhu.edu; B. Vogelstein V. E. Velculescu K. W. Kinzler (sequencing and copy number analysis) bertvog@gmail.com velculescu@jhmi.edu kinzlke@jhmi.edu. We thank N. Silliman J. Ptak L. Dobbyn and M. Whalen for assistance with PCR amplification; D. Lister L. J. Ehinger D. L. Satterfield J. D. Funkhouser and P. Killela for assistance with DNA purification; T. Sjöblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research NIH grants CA121113 NS052507 CA43460 CA57345 CA62924 CA09547 5P50-NS-20023 CA108786 and CA11898 the Pew Charitable Trusts the Pediatric Brain Tumor Foundation Institute the Hirschhorn Foundation Alex's Lemonade Stand Foundation the American Brain Tumor Association the American Society of Clinical Oncology the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme Beckman Coulter and Exact Sciences Corporations B.V. V.E.V. and K.W.K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
Cited by
Sorted by citations
Items 801–900 of 1,034
Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma
Michealraj, K. A., Kumar, S. A., Kim, L. J. Y., Cavalli, F. M. G., Przelicki, D., Wojcik, J. B., Delaidelli, A., Bajic, A., Saulnier, O., MacLeod, G. D. A. H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.047 · Cited by 142
IDH1andIDH2Mutations in Gliomas
Carli, E. D., Wang, X.-W., & Puget, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090593 · Cited by 134
Prostate cancer genomics: towards a new understanding
Witte, J. S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2507 · Cited by 136
Turner, D. A., & Adamson, D. C. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820e1152 · Cited by 133
The missing Zinc: p53 misfolding and cancer
Loh, S. N. (2010) · Metallomics · doi:10.1039/c003915b · Cited by 137
The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype
Bacco, F. D., Casanova, E., Médico, E., Pellegatta, S., Orzan, F., Albano, R., Luraghi, P., Reato, G., D'Ambrosio, A., Porrati, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3490 · Cited by 135
Alain, T., Lun, X. Q., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F. J., Lemay, C. G., Roy, D. G., Bell, J. C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912344107 · Cited by 135
H3F3A K27M Mutation in Pediatric CNS Tumors
Gielen, G. H., Gessi, M., Hammes, J., Kramm, C. M., Waha, A., & Pietsch, T. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpabohbc33fvmo · Cited by 136
Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas
Liang, S., Zhang, R., Liang, D., Song, T., Ai, T., Chen, X., Xia, L., & Wang, Y. (2018) · Genes · doi:10.3390/genes9080382 · Cited by 137
Jansen, M., Perry, A., Heffner, R. R., & Louis, D. N. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00069-4 · Cited by 133
Hubert, C. G., Bradley, R. K., Ding, Y., Toledo, C. M., Herman, J., Skutt-Kakaria, K., Girard, E. J., Davison, J., Berndt, J. D., Corrin, P. D., et al. (2013) · Genes & Development · doi:10.1101/gad.212548.112 · Cited by 134
SINGLE CELL DERIVED CLONAL ANALYSIS OF HUMAN GLIOBLASTOMA LINKS FUNCTIONAL AND GENOMIC HETEROGENEITY
Dirks, P. B., Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M. M., Bayani, J., Pressey, J. C., Lionel, A. C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.51 · Cited by 133
Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention
Zhang, Y., & Yang, J.-M. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22958 · Cited by 132
A survey of glioblastoma genomic amplifications and deletions
Rao, S. K., Edwards, J. B., Joshi, A. D., Siu, I., & Riggins, G. J. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9959-4 · Cited by 132
Self-citationMolecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 134
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
Zhang, C., Moore, L. M., Li, X., Yung, W. K. A., & Zhang, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not087 · Cited by 136
Cilibrasi, C., Riva, G., Romano, G., Cadamuro, M., Bazzoni, R., Butta, V., Paoletta, L., Dalprà, L., Strazzabosco, M., Lavitrano, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169854 · Cited by 132
Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 135
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing
Agarwal, S., Sharma, M. C., Jha, P., Pathak, P., Suri, V. S., Sarkar, C., Chosdol, K., Suri, A., Kale, S. S., Mahapatra, A. K., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not015 · Cited by 134
Pollack, I. F., Stewart, C. F., Koçak, M., Poussaint, T. Y., Broniscer, A., Banerjee, A., Douglas, J. G., Kun, L. E., Boyett, J. M., & Geyer, J. R. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq199 · Cited by 131
Liu, H., Wang, Y., Belz, T., Bock, D., Takacs, A., Radlwimmer, B., Barbus, S., Reifenberger, G., Lichter, P., & Schütz, G. (2010) · Genes & Development · doi:10.1101/gad.560310 · Cited by 131
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth
Hjelmeland, A. B., Wu, Q., Wickman, S., Eyler, C. E., Heddleston, J. M., Shi, Q., Lathia, J. D., MacSwords, J., Lee, J., McLendon, R. E., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000319 · Cited by 133
Self-citationMolecular mechanisms of temozolomide resistance in glioblastoma multiforme
Johannessen, T.-C. A., & Bjerkvig, R. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.37 · Cited by 131
Precancer Atlas to Drive Precision Prevention Trials
Spira, A. E., Yurgelun, M. B. B., Alexandrov, L. B., Rao, A., Bejar, R., Polyák, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 134
Self-citationCharacterization of gliomas: from morphology to molecules
Ferris, S. P., Hofmann, J. W., Solomon, D. A., & Perry, A. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2181-4 · Cited by 130
Zhou, H., Chang, K., Bai, H. X., Xiao, B., Su, C., Bi, W. L., Zhang, P. J., Senders, J. T., Vallières, M., Kavouridis, V. K., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03096-0 · Cited by 130
Glutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 134
Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer
Benjamin, D. I., Cravatt, B. F., & Nomura, D. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.013 · Cited by 131
Oncogenic extracellular vesicles in brain tumor progression
D’Asti, E., Garnier, D., Lee, T. H., Montermini, L., Meehan, B., & Rak, J. W. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00294 · Cited by 134
Invasion as target for therapy of glioblastoma multiforme
Vehlow, A., & Cordes, N. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.07.001 · Cited by 137
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 131
The mini-driver model of polygenic cancer evolution
Castro-Giner, F., Ratcliffe, P. J., & Tomlinson, I. P. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3999 · Cited by 133
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 131
Self-citationChu, T., Rice, E. J., Booth, G. T., Salamanca, H. H., Wang, Z., Core, L. J., Longo, S. L., Corona, R. J., Chin, L. S., Lis, J. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0244-3 · Cited by 136
Wang, Z., Gao, L., Guo, X., Feng, C., Lian, W., Deng, K., & Xing, B. (2019) · Aging · doi:10.18632/aging.102566 · Cited by 129
Chaichana, K. L., Park, P., Olivi, A., & Quiñones‐Hinojosa, A. (2009) · Journal of neurosurgery · doi:10.3171/2009.9.jns09805 · Cited by 129
Self-citationMolecular targeting of glioblastoma: Drug discovery and therapies
Bai, R.-Y., Staedtke, V., & Riggins, G. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.011 · Cited by 141
Self-citationPI3K and STAT3: A New Alliance
Vogt, P. K., & Hart, J. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0218 · Cited by 131
Bax, D. A., Little, S. E., Gaspar, N., Perryman, L., Marshall, L. V., Viana‐Pereira, M., Jones, T. A., Williams, R. D., Grigoriadis, A. E., Vassal, G., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005209 · Cited by 137
The role of autophagy in sensitizing malignant glioma cells to radiation therapy
Zhuang, W., Qin, Z., & Liang, Z. (2009) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmp028 · Cited by 130
Cohen, K. J., Jabado, N., & Grill, J. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox021 · Cited by 143
Glutamate Dehydrogenase, a Complex Enzyme at a Crucial Metabolic Branch Point
Smith, H. Q., Li, C., Stanley, C. A., & Smith, T. J. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2428-0 · Cited by 133
Role of Rad51 and DNA repair in cancer: A molecular perspective
Laurini, E., Marson, D., Fermeglia, A., Aulić, S., Fermeglia, M., & Pricl, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107492 · Cited by 135
Martinho, O., Longatto‐Filho, A., Lambros, M. B., Martins, A. M., Pinheiro, C. M., da Silva, A. S. L., Pardal, F., de Amorim, J. A., Mackay, A. G., Milanezi, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605225 · Cited by 128
DNA replication timing and selection shape the landscape of nucleotide variation in cancer genomes
Woo, Y., & Li, W. (2012) · Nature Communications · doi:10.1038/ncomms1982 · Cited by 133
Kim, J., Zhang, Y., Skalski, M., Hayes, J. L., Kefas, B. A., Schiff, D., Purow, B. W., Parsons, S. J., Lawler, S. E., & Abounader, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1449 · Cited by 127
Mig-6 controls EGFR trafficking and suppresses gliomagenesis
Ying, H., Zheng, H., Scott, K. L., Wiedemeyer, R., Yan, H., Lim, C., Huang, J. S., Dhakal, S., Ivanova, E. V., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914930107 · Cited by 131
Self-citationIsocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
CAR‐NK cells: the next wave of cellular therapy for cancer
Daher, M., Garcia, L. M., Li, Y., & Rezvani, K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1274 · Cited by 133
Edelman, L. B., Eddy, J. A., & Price, N. D. (2009) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.75 · Cited by 127
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Ralph, S. J., Moreno-Sánchez, R., Neuzil, J., & Rodríguez-Enríquez, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0566-7 · Cited by 126
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Role of RAS in the Regulation of PI 3-Kinase
Castellano, E., & Downward, J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_56 · Cited by 129
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Jhanwar‐Uniyal, M., LaBagnara, M., Friedman, M., Kwasnicki, A. M., & Murali, R. (2015) · Cancers · doi:10.3390/cancers7020538 · Cited by 130
Parrish, K., Sarkaria, J. N., & Elmquist, W. F. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.71 · Cited by 131
Galvão, R. P., Kasina, A., McNeill, R. S., Harbin, J. E., Foreman, O., Verhaak, R. G. W., Nishiyama, A., Miller, C. R., & Zong, H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414389111 · Cited by 136
Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Gaal, J., Burnichon, N., Korpershoek, E., Roncelin, I., Bertherat, J. Y., Plouin, P., de Krijger, R. R., Gimenez‐Roqueplo, A., & Dinjens, W. N. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2170 · Cited by 131
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
NF-κB and STAT3 signaling in glioma: targets for future therapies
Atkinson, G. P., Nozell, S. E., & Benveniste, E. N. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.21 · Cited by 128
Yan, X. S., Ma, L., Yi, D., Yoon, J.-G., Diercks, A. H., Foltz, G., Price, N. D., Hood, L., & Tian, Q. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018696108 · Cited by 130
Mitochondrially targeted anti-cancer agents
Biasutto, L., Dong, L., Zoratti, M., & Neužil, J. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.004 · Cited by 125
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks
Kool, J., & Berns, A. J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2647 · Cited by 125
Singh, D. K., Ku, C., Wichaidit, C., Steininger, R. J., Wu, L. F., & Altschuler, S. J. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.22 · Cited by 125
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 125
Mack, S. C., Singh, I., Wang, X., Hirsch, R. A., Wu, Q., Villagomez, R., Bernatchez, J. A., Zhu, Z., Gimple, R. C., Kim, L. J. Y., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190196 · Cited by 131
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 125
SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases
Wang, B., Ye, Y., Yang, X. P., Liu, B., Wang, Z., Chen, S., Jiang, K., Zhang, W., Jiang, H., Mustonen, H. K., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948183 · Cited by 125
Liu, S., Shah, Z., Sav, A., Russo, C., Berkovsky, S., Qian, Y., Coiera, E. W., & Ieva, A. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-64588-y · Cited by 125
Bayley, J. C., Hadley, C. C., Harmanci, A. O., Harmancı, A. S., Klisch, T. J., & Patel, A. J. (2022) · Science Advances · doi:10.1126/sciadv.abm6247 · Cited by 125
Sox11 Prevents Tumorigenesis of Glioma-Initiating Cells by Inducing Neuronal Differentiation
Hide, T., Takezaki, T., Nakatani, Y., Nakamura, H., Kuratsu, J., & Kondo, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2006 · Cited by 125
Goutagny, S., Yang, H. W., Zucman‐Rossi, J., Chan, J. A.-W., Dreyfuss, J. M., Park, P. J., Black, P. M., Giovannini, M., Carroll, R. S., & Kalamarides, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0891 · Cited by 126
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130
Self-citationThe mutational landscape of chromatin regulatory factors across 4,623 tumor samples
González-Pérez, A., Jené-Sanz, A., & López-Bigas, N. (2013) · Genome biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 131
Novel Delivery Strategies for Glioblastoma
Zhou, J., Atsina, K., Himes, B. T., Strohbehn, G. W., & Saltzman, W. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318244d8ae · Cited by 128
Xing, Z., Yang, X., She, D., Lin, Y., Zhang, Y., & Cao, D. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5171 · Cited by 124
Vengoji, R., Macha, M. A., Nimmakayala, R. K., Rachagani, S., Siddiqui, J. A., Mallya, K. B., Gorantla, S., Jain, M., Ponnusamy, M. P., Batra, S. K., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1264-2 · Cited by 127
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C. J., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 134
Self-citationAn Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 131
Wang, L. M., Englander, Z. K., Miller, M. L., & Bruce, J. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_1 · Cited by 133
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123
Morris, M. K., Sáez-Rodríguez, J., Clarke, D. C., Sorger, P. K., & Lauffenburger, D. A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001099 · Cited by 123
Icard, P., & Lincet, H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.001 · Cited by 133
Little, S. E., Popov, S., Jury, A., Bax, D. A., Doey, L. J., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4069 · Cited by 123
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta, S., Valletta, L., Corbetta, C., Patanè, M., Zucca, I., Sirtori, F. R., Bruzzone, M. G., Fogliatto, G., Isacchi, A., Pollo, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0180-0 · Cited by 123
MR Imaging–Based Analysis of Glioblastoma Multiforme: Estimation ofIDH1Mutation Status
Yamashita, K., Hiwatashi, A., Togao, O., Kikuchi, K., Hatae, R., Yoshimoto, K., Mizoguchi, M., Suzuki, S. O., Yoshiura, T., & Honda, H. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4491 · Cited by 123
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
Emir, U. E., Larkin, S. J., de Pennington, N., Voets, N., Plaha, P., Stacey, R. J., Al-Qahtani, K., McCullagh, J., Schofield, C. J., Clare, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0934 · Cited by 123
Draaisma, K., Chatzipli, A., TAPHOORN, M. J. B., Kerkhof, M., Weyerbrock, A., Sanson, M., Hoeben, A., Lukacova, S., Lombardi, G., Leenstra, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00367 · Cited by 125
PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges
Cheng, C. K., Fan, Q., & Weiss, W. A. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00233.x · Cited by 125
Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., & Gu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068782 · Cited by 127
Alterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Chaichana, K. L., Jusué-Torres, I., Lemos, A. M., Gokaslan, A. K., Cabrera‐Aldana, E. E., Ashary, A., Olivi, A., & Quiñones‐Hinojosa, A. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1597-9 · Cited by 122
Self-citationHow Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126
Fajardo, N. M. P., Meijer, C., & Kruyt, F. A. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.008 · Cited by 122
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You StrongerPreprint
Mathew, R., & White, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.011015 · Cited by 131
Metadata
- Authors
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K. N., Shinjo, S. M. O., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Corresponding author
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Angenendt, Philipp
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- ORCID
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Carter, Hannah
- Gallia, Gary L.
- Olivi, Alessandro
- McLendon, Roger
- Keir, Stephen
- Diaz, Luis A.
- Marie, Suely Kazue Nagahashi
- Yan, Hai
- Riggins, Gregory J.
- Bigner, Darell D.
- Karchin, Rachel
- Parmigiani, Giovanni
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- Venue
- Science
- Published
- 2008-09-26
- Volume
- 321
- Issue
- 5897
- Pages
- 1807-1812
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820389
- OpenAlex
- W2040827479
- Cited by
- 5,857
- References
- 51
- Citations by year
- 2026: 131 · 2025: 160 · 2024: 189 · 2023: 260 · 2022: 256 · 2021: 370 · 2020: 344 · 2019: 313 · 2018: 329 · 2017: 347 · 2016: 353 · 2015: 373 · 2014: 410 · 2013: 428 · 2012: 457
- FWCI
- 172.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- National Cancer Institute (CA108786., CA 57345, R01-CA121113, CA-121113, CA43460, CA-11898, R37CA043460, CA09547, P50CA108786, R01CA140316, P50CA062924, R37CA057345, T32CA009547, CA 62924)
- National Institute of Neurological Disorders and Stroke (5P50NS20023, R01NS052507, NS052507)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, IDH1 mutation, IDH1, somatic mutations, gene amplification, gene deletion, gene expression profiling, secondary glioblastoma, overall survival, targeted therapy
- MeSH terms
- Adult, Brain Neoplasms, Female, Gene Amplification, Glioblastoma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Rate, Sequence Analysis, DNA, Gene Dosage, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
